Table 1 Clinical characteristics of lung cancer and COPD patients
Lung cancer without COPD | Lung cancer with COPD | COPD | p-value | |
|---|---|---|---|---|
Number of patients (%) | 92 (44.4%) | 115 (55.6%) | 42 | |
Age on randomization, y | ||||
median | 67.5 | 65.8 | 70 | p = 0.175 |
< 59 | 23 (25%) | 21 (18.3%) | 6 (14.3%) | |
60–69 | 35 (38%) | 58 (50.4%) | 14 (33.3%) | |
70+ | 34 (37%) | 36 (31.3%) | 22 (52.4%) | |
Sex | ||||
Female | 41 (45%) | 52 (45%) | 23 (55%) | p = 0.237 |
Male | 51 (55%) | 63 (55%) | 19 (45%) | |
COPD 2017 classification | ||||
II Moderate (FEV1 50–80%) | 99 (86.1%) | 16 (38%) | p < 0.001 | |
III Severe (FEV1 30–50%) | 15 (13%) | 18 (43%) | ||
IV Very severe (FEV1 < 30%) | 1 (0.9%) | 8 (19%) | ||
Steroids | ||||
Oral | No info | No info | 4 (9.5%) | |
Inhalation | No info | No info | 27 (64.3%) | |
No steroids | 11(26.2%) | |||
Smoking status | ||||
Never | 9 (9.8%) | 1 (0.9%) | 3 (7%) | p = 0.016 |
Former | 57 (62%) | 65 (56.5%) | 29 (69%) | |
Current | 26 (28.2%) | 49 (42.6%) | 10 (24%) | |
Pack-years smoked among former/current smokers | 83 | 114 | 39 | p = 0.008 |
< 30 | 47 (57%) | 44 (39%) | 11 (29%) | |
30–39 | 16 (20%) | 28 (25%) | 10 (26%) | |
40–49 | 4 (5%) | 20 (18%) | 11 (29%) | |
50+ | 15 (18%) | 22 (19%) | 6 (16%) | |
No information | 1 | 1 | ||
Never smokers | 9 | 1 | 3 | |
Lung cancer histology | ||||
Squamous cell carcinoma | 35 (38%) | 69 (60%) | p = 0.001 | |
Adenocarcinoma | 57 (62%) | 46 (40%) | ||
Lung cancer stage | ||||
I | 46 (50%) | 72 (62.6%) | p = 0.105 | |
II | 28 (30%) | 25 (21.7%) | ||
III | 16 (17%) | 17 (14.8%) | ||
IV | 2 (3%) | 1 (0.9%) | ||
5-year survival | 54 (59%) | 68 (59%) | ||